Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma.
about
The Warburg effect and drug resistanceIntegration of Mitochondrial Targeting for Molecular Cancer TherapeuticsTargeting Tumor Metabolism for Cancer Treatment: Is Pyruvate Dehydrogenase Kinases (PDKs) a Viable Anticancer Target?Metabolic interplay between glycolysis and mitochondrial oxidation: The reverse Warburg effect and its therapeutic implicationRestoration of mitochondria function as a target for cancer therapyLinking metabolism and epigenetic regulation in development of hepatocellular carcinomaMetabolic and hypoxic adaptation to anti-angiogenic therapy: a target for induced essentialityROS homeostasis and metabolism: a critical liaison for cancer therapyInhibition of lipolysis by mercaptoacetate and etomoxir specifically sensitize drug-resistant lung adenocarcinoma cell to paclitaxelPro-haloacetate Nanoparticles for Efficient Cancer Therapy via Pyruvate Dehydrogenase Kinase ModulationIncreased mitochondrial activity in renal proximal tubule cells from young spontaneously hypertensive ratsDichloroacetate induces autophagy in colorectal cancer cells and tumours.MEIS1 regulates an HLF-oxidative stress axis in MLL-fusion gene leukemia.Phase 1 trial of dichloroacetate (DCA) in adults with recurrent malignant brain tumors.By reducing hexokinase 2, resveratrol induces apoptosis in HCC cells addicted to aerobic glycolysis and inhibits tumor growth in mice.Quantitative proteomics and phosphoproteomics on serial tumor biopsies from a sorafenib-treated HCC patientTargeting glucose metabolism in cancer: new class of agents for loco-regional and systemic therapy of liver cancer and beyond?Modulation of anti-cancer drug sensitivity through the regulation of mitochondrial activity by adenylate kinase 4.In vitro and in vivo study of epigallocatechin-3-gallate-induced apoptosis in aerobic glycolytic hepatocellular carcinoma cells involving inhibition of phosphofructokinase activity.A new mechanism of trastuzumab resistance in gastric cancer: MACC1 promotes the Warburg effect via activation of the PI3K/AKT signaling pathwayPhosphorylation of the pyruvate dehydrogenase complex precedes HIF-1-mediated effects and pyruvate dehydrogenase kinase 1 upregulation during the first hours of hypoxic treatment in hepatocellular carcinoma cells.A network-based phenotype mapping approach to identify genes that modulate drug response phenotypes.Systems biology analysis of drivers underlying hallmarks of cancer cell metabolism.Deregulation of glycolysis in cancer: glyceraldehyde-3-phosphate dehydrogenase as a therapeutic target.Targeting VDAC-bound hexokinase II: a promising approach for concomitant anti-cancer therapy.The pyruvate dehydrogenase complex in cancer: An old metabolic gatekeeper regulated by new pathways and pharmacological agents.Chemotherapeutic xCT inhibitors sorafenib and erastin unraveled with the synaptic optogenetic function analysis toolComplex I inhibition augments dichloroacetate cytotoxicity through enhancing oxidative stress in VM-M3 glioblastoma cells.A phase I open-labeled, single-arm, dose-escalation, study of dichloroacetate (DCA) in patients with advanced solid tumors.Effects of sorafenib on energy metabolism in breast cancer cells: role of AMPK-mTORC1 signaling.GSTZ1 expression and chloride concentrations modulate sensitivity of cancer cells to dichloroacetate.Inhibition of autophagy enhances the selective anti-cancer activity of tigecycline to overcome drug resistance in the treatment of chronic myeloid leukemiaSorafenib and 2-Deoxyglucose Synergistically Inhibit Proliferation of Both Sorafenib-Sensitive and -Resistant HCC Cells by Inhibiting ATP Production.Hepatocellular carcinoma and sorafenib: too many resistance mechanisms?Single cell cloning generates lung endothelial colonies with conserved growth, angiogenic, and bioenergetic characteristics.By inhibiting PFKFB3, aspirin overcomes sorafenib resistance in hepatocellular carcinoma.Identification of sequence polymorphisms in the mitochondrial cytochrome c oxidase genes as risk factors for hepatocellular carcinoma.Genistein suppresses aerobic glycolysis and induces hepatocellular carcinoma cell death.Latent carcinogenicity of early-life exposure to dichloroacetic acid in mice.
P2860
Q26770007-38F60FFE-D7FB-439A-97B3-EB5D349670CEQ26771751-2EFAFCEE-3752-42FC-AE8B-870D2E4C892EQ26774957-F8201FB3-3751-4FD1-BB99-D4E7FA232038Q26795759-9B51907D-16B6-4305-9200-9BB56A0CA83AQ26864167-5519E905-A927-4FC3-9E2D-73C8FB519C8DQ27023744-BF9F5510-BEF9-4F3B-86F7-FCFA990AB88DQ27025007-CAE86599-12DE-40E3-86ED-98B7A684D8F4Q28080316-285CD2B0-BF81-4112-8BE1-F88B23692AC9Q28533247-8AB7A019-5DDE-408E-B1B3-CFF05C5D565CQ28829603-361D58DA-6144-4425-8381-9EDBC47CA995Q30411075-6B56C704-F549-48DE-9919-EE825CB207A6Q33918095-112F51A5-D412-4F8D-8ADA-36ED4726E133Q35450566-F3A66EB1-7585-4DFC-B91A-C7350AA7AE6BQ35684292-AAF36FD7-70E3-49BB-8E1A-1D5D729D865AQ35955419-D276CE91-99F2-4531-8CD9-70C1C82DC993Q36563432-541DB6D9-31A9-4757-B226-34A76BC5BA5DQ36687966-0EB98C94-E200-4DD3-BAF6-5B351828233BQ36691864-26A5DFEE-77E4-448A-9E60-3D8DCD0A6E50Q37044525-3252DF74-492C-4F1D-97D6-AA817E085CB7Q37224355-CA345871-6A22-4F57-BB73-F81D9E9C6E24Q37376764-6C15B15C-CA98-412A-A0EA-78C05957B72EQ37411962-D08C8E3A-7AE2-4376-8DE0-1E050962BD4DQ37604410-706F2379-337D-4BEE-9B1B-DA77E2BC3F44Q38085071-6CAE3566-D203-4CF6-A4F8-D1AF76C2F319Q38132274-66EC6ACF-45C4-47F3-BC78-BC0ACA42CF40Q38418672-F0534363-AB4E-4C72-A5CC-82F26FF5825BQ38611037-C2E3DE30-AA09-4B66-85FF-64396C6AFB5DQ38711927-8C947CAE-0B7D-49C4-B696-344B4D6A689DQ39030297-E4242456-EE83-4D4F-93C3-34FB85001A27Q39107424-E660932C-891F-406D-9445-25F38CF884D2Q40359726-3273AE9D-4719-443C-9DA4-88B4B27CEDD3Q42317181-7B73E5B5-D320-427A-A294-CD379B5F6933Q42323382-F20E00D2-367B-4049-91CF-68F40211A1C0Q44659249-DF66E910-3420-4095-A73A-7C0FDCAA3441Q47133004-EE3E7732-E9BA-4B1B-B710-DF933E3E092EQ47878727-DCC8B44B-1B75-4670-B297-6D7EA155EBA3Q48133485-481C04B6-F8F7-4FF3-9661-079F43527226Q50020458-D3FB9185-5C0D-4187-A0E3-B201056272BEQ51030086-351F3B7B-9F66-46FD-AA2B-02644AB1659C
P2860
Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Activating oxidative phosphory ...... e of hepatocellular carcinoma.
@ast
Activating oxidative phosphory ...... e of hepatocellular carcinoma.
@en
type
label
Activating oxidative phosphory ...... e of hepatocellular carcinoma.
@ast
Activating oxidative phosphory ...... e of hepatocellular carcinoma.
@en
prefLabel
Activating oxidative phosphory ...... e of hepatocellular carcinoma.
@ast
Activating oxidative phosphory ...... e of hepatocellular carcinoma.
@en
P2093
P2860
P356
P1476
Activating oxidative phosphory ...... e of hepatocellular carcinoma.
@en
P2093
P2860
P2888
P356
10.1038/BJC.2012.559
P407
P577
2012-12-20T00:00:00Z